Induction and exacerbation of psoriasis with Interferon‐alpha therapy for hepatitis C: A review and analysis of 36 cases

Background  Interferon‐alpha (IFN‐α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN‐α is increasingly recognized, but the distinct associated features, aetiology and management have not been reviewed.

[1]  C. Geisler,et al.  Increased sensitivity to interferon-alpha in psoriatic T cells. , 2005, The Journal of investigative dermatology.

[2]  L. Rostaing,et al.  Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? , 2006, Transplantation proceedings.

[3]  V. Chong.  Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for chronic hepatitis C infection. , 2011, Singapore medical journal.

[4]  H. Deicher,et al.  Psoriasis-Exazerbation bei Therapie mit α-Interferon , 2008 .

[5]  W. White,et al.  A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. , 2010, Journal of the American Academy of Dermatology.

[6]  C. Weeks,et al.  Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. , 1994, Journal of interferon research.

[7]  R. Dummer,et al.  Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. , 2004, Archives of dermatology.

[8]  M. Piga,et al.  [IFN-alpha-induced psoriatic arthritis and HCV-related liver cirrhosis. Therapeutic options and patient's opinion]. , 2011, Reumatismo.

[9]  D P West,et al.  Chronic active hepatitis associated with etretinate therapy , 1985, The British journal of dermatology.

[10]  G. Magro,et al.  Verrucous Psoriasis in a Patient with Chronic C Hepatitis Treated with Interferon , 2004, Clinical drug investigation.

[11]  M. Wiselka,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C , 2000, Postgraduate medical journal.

[12]  Charlotte Hubbard,et al.  Introducing Journal of Medical Case Reports , 2007, Journal of medical case reports.

[13]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[14]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[15]  J. Dreiher,et al.  Psoriasis Associated with Hepatitis C but Not with Hepatitis B , 2010, Dermatology.

[16]  J. Langtry,et al.  Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas , 2006, Clinical and experimental dermatology.

[17]  F. Pérez Roldán,et al.  [Interferon-alpha and development of psoriatic arthropathy]. , 1996, Anales de Medicina Interna.

[18]  G. Webster,et al.  Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. , 1993, The American journal of gastroenterology.

[19]  E. Schrumpf,et al.  Psoriasis induced by interferon‐α , 1991 .

[20]  W. Diezel,et al.  Detection of interferon in the sera of patients with psoriasis, and its enhancement by PUVA treatment , 1983, The British journal of dermatology.

[21]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[22]  T. Taniguchi,et al.  CD8 (+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-α/β signaling , 2000 .

[23]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[24]  Y. Makino,et al.  Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. , 1994, The Journal of rheumatology.

[25]  Meng-Chi Wu,et al.  Generalized flare of pustular psoriasis induced by PEGylated interferon‐α2b therapy for chronic hepatitis C , 2012, The Australasian journal of dermatology.

[26]  H. Okamoto,et al.  Hepatitis C virus infection in patients with psoriasis. , 1996, Archives of dermatology.

[27]  M. López-Escobar,et al.  Psoriasis inducida por interferón alfa pegilado , 2007 .

[28]  J. Quesada,et al.  PSORIASIS AND ALPHA-INTERFERON , 1986, The Lancet.

[29]  M. Martinka,et al.  Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. , 2007, Archives of dermatology.

[30]  N. Curco,et al.  Psoriasis with articular involvement induced by interferon alfa. , 1991, Archives of dermatology.

[31]  M. López-Nevot,et al.  Interferon-induced psoriasis in a patient with chronic hepatitis C. , 1993, Dermatology.

[32]  M. Gumbs,et al.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis , 2000 .

[33]  E. Dika,et al.  Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod , 2006, International journal of dermatology.

[34]  A. Gurney,et al.  IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes1 , 2005, The Journal of Immunology.

[35]  A. Richetta,et al.  Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab , 2009, Dermatologic therapy.

[36]  E. Torres,et al.  Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. , 2008, Puerto Rico Health Sciences Journal.

[37]  F. Belardelli,et al.  Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12 , 2011, PloS one.

[38]  H. Shimizu,et al.  Generalized pustular psoriasis and Hepatitis C virus infection. , 2004, Acta virologica.

[39]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[40]  G. Siller,et al.  Psoriasis induced by topical imiquimod , 2004, Australasian Journal of Dermatology.

[41]  I. Shah,et al.  Prevalence of hepatotrophic viruses b&c in psoriasis -A study from kashmir , 2005 .

[42]  R. Bergman,et al.  Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha. , 2009, Journal of dermatological science.

[43]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[44]  Niu Jun-q.  Interpretation:An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases , 2011 .

[45]  S. Şahin,et al.  Concomitant Vitiligo and Psoriasis in a Patient Treated with Interferon Alfa‐2a for Chronic Hepatitis B Infection , 2004, Pediatric dermatology.

[46]  A. Lok,et al.  Interferon-free treatment regimens for hepatitis C: are we there yet? , 2011, Gastroenterology.

[47]  P. Martín,et al.  Exacerbation of psoriasis due to interferon-α treatment of chronic active hepatitis , 1993 .

[48]  V. Levine,et al.  Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism , 2011, The British journal of dermatology.

[49]  M. Degré,et al.  Interferon in suction blister fluid from psoriatic lesions , 1983, The British journal of dermatology.

[50]  M. Galeazzi,et al.  Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection , 2007, Clinical Rheumatology.

[51]  W. Kim,et al.  The burden of hepatitis C in the United States , 2002, Hepatology.

[52]  M. Başkol,et al.  Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. , 2007, European journal of gastroenterology & hepatology.

[53]  R. Cecchi,et al.  Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). , 2006, Dermatology online journal.

[54]  G. Alexander,et al.  Chronic hepatitis C infection and psoriasis. , 1995, Dermatology.

[55]  M. Yamamura,et al.  The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. , 1993, The Journal of investigative dermatology.

[56]  J. Hoofnagle,et al.  National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 , 2002, Hepatology.

[57]  A. Gottlieb,et al.  Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases , 2009, The Journal of dermatological treatment.

[58]  A. Gottlieb,et al.  Etanercept therapy in patients with autoimmunity and hepatitis C , 2003, The Journal of dermatological treatment.

[59]  R. Manfredi,et al.  Overwhelming diffuse psoriasis during chronic HCV infection, after peginterferon-ribavirin treatment, supported by frequent resort to filgrastim rescue. , 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[60]  S. Sookoian,et al.  HEPATITIS C VIRUS ANTIBODY (ANTI‐HCV): PREVALENCE IN PSORIASIS , 1996, International journal of dermatology.

[61]  G. Pasero,et al.  Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. , 1999, The Journal of rheumatology.

[62]  L. van der Fits,et al.  Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor‐2 (IRF‐2) , 2003, The Journal of pathology.

[63]  G. Pozzato,et al.  Psoriasis exacerbation induced by interferon-alpha. Report of two cases. , 1993, Acta dermato-venereologica.

[64]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[65]  A. Gottlieb,et al.  Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. , 2009, Journal of the American Academy of Dermatology.

[66]  M. Gilliet,et al.  Antimicrobial peptides and self-DNA in autoimmune skin inflammation. , 2008, Current opinion in immunology.

[67]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[68]  A. Di Nardo,et al.  Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons , 2010, The Journal of experimental medicine.

[69]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[70]  D. Meyer‐Olson,et al.  Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis , 2010, Annals of the rheumatic diseases.

[71]  A. Downs,et al.  Exacerbation of psoriasis by interferon‐alpha therapy for hepatitis C , 2000, Clinical and experimental dermatology.

[72]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[74]  I. Olivieri,et al.  Hepatitis C virus infection in psoriatic arthritis. , 2005, Arthritis and rheumatism.

[75]  D. Piccolo,et al.  Effective control of psoriasis by etanercept in a patient with HCV-related diseases. , 2008, European journal of dermatology : EJD.

[76]  G. Pasero,et al.  Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. , 1997, Scandinavian journal of rheumatology.

[77]  G. ClementeRicote,et al.  [Interferon-alpha and development of psoriatic arthropathy]. , 1996 .

[78]  G. Usluer,et al.  Exacerbation of Psoriasis due to Peginterferon alpha-2b plus Ribavirin Treatment of Chronic Active Hepatitis C , 2005, Chemotherapy.

[79]  M. Degré,et al.  Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy. , 1994, Acta dermato-venereologica. Supplementum.

[80]  L. van der Fits,et al.  In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. , 2004, The Journal of investigative dermatology.

[81]  H. Conjeevaram,et al.  A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C , 2002, Hepatology.

[82]  E. Jeffes,et al.  Etanercept as prophylactic psoriatic therapy before interferon‐α and ribavirin treatment for active hepatitis C infection , 2010, Clinical and experimental dermatology.

[83]  B. Jakšić,et al.  Exacerbation of psoriasis after treatment with alpha-interferon. , 1990, Dermatologica.

[84]  A. Gottlieb,et al.  Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. , 2004, Journal of the American Academy of Dermatology.

[85]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[86]  A. Barton,et al.  Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy , 2012, The British journal of dermatology.

[87]  I. Elefsiniotis,et al.  Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. , 2005, European journal of dermatology : EJD.

[88]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.

[89]  A. Karaduman,et al.  Psoriasis Associated with HCV and Exacerbated by Interferon Alpha: Complete Clearance with Acitretin during Interferon Alpha Treatment for Chronic Active Hepatitis , 2000, Dermatology.

[90]  K. Nishioka,et al.  Psoriasis and hepatitis C virus. , 1995, Acta dermato-venereologica.

[91]  Stephen L. Chen,et al.  The Natural History of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.

[92]  F. Nestle,et al.  Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. , 1994, The Journal of clinical investigation.

[93]  S. Goerdt,et al.  Interferon-α-induzierte Psoriasis vulgaris , 1996, Der Hautarzt.

[94]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[95]  M. López-Escobar,et al.  [Pegylated interferon alfa-induced psoriasis]. , 2007, Medicina clínica (Ed. impresa).

[96]  C. De Simone,et al.  Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. , 2006, Journal of the American Academy of Dermatology.

[97]  C. Geisler,et al.  Increased sensitivity to interferon-α in psoriatic T cells , 2005 .